Wockhardt Limited is all set to launch its insulin brand as it currently completed the trials and awaits the approval from the Drug Controller General of India (DCGI). Christened as Winsulin, the insulin has been developed indigenously using the recombinant technology.

Company sources claimed that the insulin will be launched as soon as the DCGI approval comes.

The launch comes at a time when two major players Eli Lilly and Novo Nordisk have slashed the prices of their respective versions of insulin. The pricing of Winsulin was not revealed but according to industry sources, it may be in the same range as that of two above mentioned companies.

In the meanwhile, two other Indian companies, Shanta- Biocon and Bharat Biotech, have also announced that they would be entering the domestic market with their version of insulin. The respective launch has not been revealed. The entry of Winsulin thus would heat up the competition in the domestic insulin market. Shanta Biocon is a joint venture
between Shanta Biotechnics, which was the first to launch the indigenous version of Hepatitis B vaccine, and Biocon India Ltd , a major player in the statin market. Bharat Biotech is also a player in the Hepatitis B vaccine market.